In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and Vertex Pharmaceuticals (VRTX ... has a Zacks Rank of #2 (Buy), while Vertex ...

Vertex Pharmaceuticals (VRTX) shares soared 5.3% in the last trading ... Revenues are expected to be $2.77 billion, up 10.2% from the year-ago quarter. While earnings and revenue growth ...

Vertex Pharmaceuticals, Inc. shares are currently trading up about 6.2% on the day. The chart below shows the one year performance of VRTX shares, versus its 200 day moving average: ...

especially as income from Casgevy remains low in the near term, helping to diversify its commercial portfolio. Price Action: VRTX stock is down 0.46% at $411.47 at the last check on Tuesday.

We are so very pleased to be in Phase 3 development. We converted the Phase 1, 2, 3 study into a Phase 3 study after global regulatory discussions, including with the FDA. The Phase 3 pivotal ...